Alexion Pharmaceuticals Inc.

06/11/2021 | Press release | Distributed by Public on 06/11/2021 01:04

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021